Heteroaryldiazepine derivatives as RSV inhibitors
US10398706B2 · kind B2 · utility
25Cited by
3References
11Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 5, 2018 |
| Grant date | Sep 3, 2019 |
| Priority date | — |
| Expiry date | Jan 5, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D495/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, esters, or prodrugs thereof: These compounds are useful for treating Respiratory Syncytial Virus (RSV) infection. The present invention further relates to pharmaceutical compositions comprising these compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering to the subject a pharmaceutical composition comprising a compound of the invention.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.